MARCH 28, 2024
Annual and Sustainability Report 2023
Key News
MARCH 15, 2024
Notice to attend the 2024 Annual General Meeting on April 26
MARCH 13, 2024
Orexo has successfully issued secured social bonds of SEK 500 m
Orexo has established a social financing framework
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products